Back to Search
DAVID PROVENCHER, M.D.
M.D.
Allergy & Immunology Physician
NPI: 1326098120Individual
Specialties, Licenses & Credentials
Pediatric Allergy/Immunology Physician
Pediatrics — Pediatric Allergy/Immunology
Code: 2080P0201X
ME81615(FL)
Allergy & Immunology PhysicianPrimary
Allergy & Immunology
Code: 207K00000X
ME81615(FL)
Research & Publications (20)
Fever of unknown origin and neutropenia in a young boy.
PMID 12452200·Ann Allergy Asthma Immunol·2002
5-case
BMP-2 signaling in ovarian cancer and its association with poor prognosis.
PMID 19366455·J Ovarian Res·2009
8-other
The chemiluminescence based Ziplex automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip expression profiles.
PMID 19580657·J Transl Med·2009
8-other
Experiences and decisions that motivate women at increased risk of breast cancer to participate in an experimental screening program.
PMID 19219540·J Genet Couns·2009
4-observational
Characterization of the 3p12.3-pcen region associated with tumor suppression in a novel ovarian cancer cell line model genetically modified by chromosome 3 fragment transfer.
PMID 19347865·Mol Carcinog·2009
4-observational
Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study.
PMID 19520420·Gynecol Oncol·2009
3-trial
Reprogramming of the transcriptome in a novel chromosome 3 transfer tumor suppressor ovarian cancer cell line model affected molecular networks that are characteristic of ovarian cancer.
PMID 19123201·Mol Carcinog·2009
8-other
Positive adnexal or uterine serosal involvement in stage IIIC endometrial cancer is an adverse factor for recurrence.
PMID 19088481·Gynecol Obstet Invest·2009
4-observational
Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.
PMID 19509545·Int J Gynecol Cancer·2009
8-other
Characterization of three new serous epithelial ovarian cancer cell lines.
PMID 18507860·BMC Cancer·2008
7-preclinical
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
PMID 18591547·J Clin Oncol·2008
3-trial
Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines.
PMID 18687136·BMC Med Genomics·2008
8-other
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent.
PMID 18402691·BMC Cancer·2008
8-other
Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.
PMID 17620309·Mol Carcinog·2008
8-other
Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia.
PMID 18351579·Int J Cancer·2008
8-other
BTF4/BTNA3.2 and GCS as candidate mRNA prognostic markers in epithelial ovarian cancer.
PMID 18398031·Cancer Epidemiol Biomarkers Prev·2008
8-other
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors.
PMID 19032793·BMC Cancer·2008
8-other
Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families.
PMID 17541742·Breast Cancer Res Treat·2008
8-other
Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro.
PMID 17894888·Reprod Biol Endocrinol·2007
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 106 SOUTHERN OAK DRIVE
PLANT CITY, FL 33563 - Phone
- (813) 752-8595
Quick Facts
- NPI
- 1326098120
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile